VSTM logo

VSTM
Verastem Inc

24,052
Mkt Cap
$491M
Volume
1.6M
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.60
VSTM Fundamentals
Price
$5.31
Prev Close
$5.59
Open
$5.58
50D MA
$5.82
Beta
1.33
Avg. Volume
2.26M
EPS (Annual)
-$3.02
P/B
7.22
Rev/Employee
$303,078.43
$417.24
Loading...
Loading...
News
all
press releases
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Verastem from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Verastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG Research
BTIG Research reiterated a "buy" rating and issued a $19.00 target price on shares of Verastem in a research report on Friday...
MarketBeat·15h ago
News Placeholder
Verastem's (VSTM) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Verastem in a report on Friday...
MarketBeat·15h ago
News Placeholder
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced two-year median follow-up data...
Business Wire·22h ago
News Placeholder
SG Americas Securities LLC Purchases 378,958 Shares of Verastem, Inc. $VSTM
SG Americas Securities LLC increased its position in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) by 3,333.8% in the fourth quarter, according to its most recent 13F filing with the...
MarketBeat·7d ago
News Placeholder
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted...
Business Wire·9d ago
News Placeholder
Verastem's (VSTM) "Buy" Rating Reaffirmed at Jefferies Financial Group
Jefferies Financial Group reissued a "buy" rating and issued a $15.00 target price (down from $19.00) on shares of Verastem in a research note on Monday...
MarketBeat·12d ago
News Placeholder
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Analysts
Shares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have been assigned a consensus rating of "Buy" from the ten research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five h...
MarketBeat·12d ago
News Placeholder
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
Zacks·16d ago
News Placeholder
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple abstracts have been...
Business Wire·24d ago
<
1
2
...
>

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.